


Teu



PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1313-D)

In the Application of:

Kopreski

Serial No.: 10/616,210

Filing Date: July 8, 2003

For: Method for Detection of 5T4
RNA In Plasma or Serum

)
)
)
)
)
)
)
)
)
)
)

Examiner: F. Lu

Group Art Unit: 1634

TRANSMITTAL LETTER


Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

- In regard to the above identified application,
1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449; and cited references
 - c) Return postcard
 2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
 3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313 on November 4, 2005.

Date: November 4, 2005

Respectfully submitted,


Kevin E. Noonan

Registration No. 35,303



PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1313-D)

In the Application of:

Kopreski

Serial No.: 10/616,210

Filing Date: July 8, 2003

**For: Method for Detection of 5T4
RNA In Plasma or Serum**

)
)
)
)
)
)
)
)
)
)
)

Examiner: F. Lu

Group Art Unit: 1634

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Date: November 4, 2005

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Kevin E. Noonan
Reg. No. 35,303

Substitute for form 1449A/PTO <div style="text-align: center;">  </div> <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
		Application No.	10/616,210		
		Filing Date:	July 8, 2003		
		First Named Inventor	Kopreski		
		Group Art Unit	1634		
		Examiner Name	F. Lu		
		Attorney Docket No.	00-1313-D		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
		5,576,178	A	Emanuel et al.	11-1996	
		5,869,053	A	Stern et al.	2-1999	
		6,329,179	B1	Kopreski	12-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	0 336 582	A	Cancer Research Campaign Technology Ltd.	03-03-1989		
		WO	97/35589	A	Michael Kopreski	10-02-1997		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SOUTHALL <i>et al.</i> "Immunohistological distribution of 5T4 antigen in normal and malignant tissue, Br. J. Cancer 61:89-95 (1990).	
		MYERS <i>et al.</i> "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein." J. Biol. Chem. 269:9319-24 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/616,210
				Filing Date:	July 8, 2003
				First Named Inventor	Kopreski
				Group Art Unit	1634
				Examiner Name	F. Lu
Sheet	2	of	2	Attorney Docket No.	00-1313-D

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
		KOPRESKI et al., "Circulating RNA as a tumor marker," Clinical Chemistry, vol. 47, no. 2, page 362, February 2000.		
		KING et al., "Organization of the mouse and human 5T oncofoetal leucine-rich glycoprotein genes and expression in foetal and adult murine tissues", Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier, Amsterdam, NL, vol. 1445, no. 3, June 9, 1999, pages 257-270.		
		PFLEIDERER et al., "Detection of Tumor Cells in Peripheral Blood and Bone Marrow from Ewing Tumour Patients by Rt-PCR." Int. J. Cancer (Red. Oncol.) 1995, 64:135-139.		
		KOMEDA et al. "Sensitive Detection of Circulating Hepatocellular Carcinoma Cells in Peripheral Venous Blood," Cancer 75:2214-19. (1999).		
		KOPRESKI et al., "Detection of Tumor Messenger RNA in the Serum of Patients with Malignant Melanoma," Clinical Cancer Research, 5:1961-65 (August 1999).		
		HASSELMANN et al., "Detection of Tumor-Associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma," Oncology Report, 8:115-118. (2001).		
		DATTA et al., "Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction" J. Clin. Oncology 12:475-482 (1994).		
		WIECZOREK et al., "Diagnostic and prognostic value of RNA-Proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker" Cancer Res. 47:6407-12 (1987).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231